The first approach of a malaria peptide vaccine was a polymeric chimeric molecule named SPf66, which conferred limited protective efficacy in monkey and human trial 1. Apical membrane antigen-1 is a protein found in the merozoite stage of the malaria parasite Plasmodium falciparum and has been shown to be critical in the invasion of host erythrocytes. Using a random peptide library displayed on the surface of phage, several peptides were identified which specifically recognized and bound to P. falciparum antigen 2. Different malaria peptide specific antibodies were obtained both by affinity-purification from malaria immune sera and by immunization of mice and these peptide candidates are used as vaccine candidates for malaria. Malaria peptides that are used as therapeutic purpose are Malaria CSP (334 - 342), Malaria aspartyl proteinase FRET substrate I, MSP - 1 P2, Malaria merozoite surface peptide – 1, peptides from circumsporozoite (CS) Protein, hemoglobin, 3037a etc.